Date:	4/22/2022	
Your Name:	Keita Takizawa	
Manuscript Title:	Treatment of trigeminal neuralgia in older adults: a narrative review	
	based on literature published between 2005 and 2021.	
Manuscript Number (if known):	JOMA-2022-OP-01(JOMA-22-2)	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	relat	tionship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	ng of the work
All support for the present	X	None	
funding,			
provision of			Click the tab key to add additional rows.
medical writing, article processing charges, etc.) No time limit for this item.			
		Time frame: past 36 mor	ths
Grants or contracts from	X	None	
indicated in item #1 above).			
	the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in	the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑ None	
4	Consulting fees	☑   None     □   □     □   □     □   □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑   None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	☑   None     □   □     □   □	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑   None     □   □     □   □	
10	Leadership or fiduciary role in	🗶 None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     □   □     □   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □	
13	Other financial or non-financial interests	□ None	
Plea		next to the following statement to indicate your re answered every question and have not altered th	

Date:	4/22/2022	
Your Name:	Kana Ozasa	
Manuscript Title:	Treatment of trigeminal neuralgia in older adults: a narrative review	
	based on literature published between 2005 and 2021.	
Manuscript Number (if known):	JOMA-2022-OP-01(JOMA-22-2)	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	relat	tionship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	ng of the work
All support for the present	X	None	
funding,			
provision of			Click the tab key to add additional rows.
medical writing, article processing charges, etc.) No time limit for this item.			
		Time frame: past 36 mor	ths
Grants or contracts from	X	None	
indicated in item #1 above).			
	the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in	the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑ None	
4	Consulting fees	☑   None     □   □     □   □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑   None     ☑   □	
6	Payment for expert testimony	☑   None	
7	Support for attending meetings and/or travel	☑   None     □   □     □   □	
8	Patents planned, issued or pending	☑ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑   None     □   □	
10	Leadership or fiduciary role in	🗷 None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     □   □     □   □     □   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □	
13	Other financial or non-financial interests	□ None	
Plea		next to the following statement to indicate your re answered every question and have not altered th	

Date:	4/22/2022	
Your Name:	Jui yen Chen	
Manuscript Title:	Treatment of trigeminal neuralgia in older adults: a narrative review	
	based on literature published between 2005 and 2021.	
Manuscript Number (if known):	JOMA-2022-OP-01(JOMA-22-2)	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	relat	tionship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	ng of the work
All support for the present	X	None	
funding,			
provision of			Click the tab key to add additional rows.
medical writing, article processing charges, etc.) No time limit for this item.			
		Time frame: past 36 mor	ths
Grants or contracts from	X	None	
indicated in item #1 above).			
	the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in	the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑ None	
4	Consulting fees	☑   None     □   □     □   □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑   None     ☑   □	
6	Payment for expert testimony	☑   None     □   □	
7	Support for attending meetings and/or travel	☑   None     □   □     □   □	
8	Patents planned, issued or pending	☑ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑ None	
10	Leadership or fiduciary role in	🗷 None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     □   □     □   □     □   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑ None	
13	Other financial or non-financial interests	□ None	
Plea		next to the following statement to indicate your a e answered every question and have not altered th	

Date:	4/22/2022
Your Name:	Rena Tanaka
Manuscript Title:	Treatment of trigeminal neuralgia in older adults: a narrative review
	based on literature published between 2005 and 2021.
Manuscript Number (if known):	JOMA-2022-OP-01(JOMA-22-2)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	relat	tionship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	ng of the work
All support for the present	X	None	
funding,			
provision of			Click the tab key to add additional rows.
medical writing, article processing charges, etc.) No time limit for this item.			
		Time frame: past 36 mor	ths
Grants or contracts from	X	None	
indicated in item #1 above).			
	the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in	the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑ None	
4	Consulting fees	☑   None     □   □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑   None     □   □     □   □	
6	Payment for expert testimony	☑ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	☑   None     □   □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑   None     □   □	
10	Leadership or fiduciary role in	🗷 None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     □   □     □   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □	
13	Other financial or non-financial interests	□ None	
Plea		next to the following statement to indicate your re answered every question and have not altered th	

Date:	4/22/2022
Your Name:	Zhimin Yan
Manuscript Title: Treatment of trigeminal neuralgia in older adults: a narrative rev	
	based on literature published between 2005 and 2021.
Manuscript Number (if known):	JOMA-2022-OP-01(JOMA-22-2)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	relat	tionship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	ng of the work
All support for the present	X	None	
funding,			
provision of			Click the tab key to add additional rows.
medical writing, article processing charges, etc.) No time limit for this item.			
		Time frame: past 36 mor	ths
Grants or contracts from	X	None	
indicated in item #1 above).			
	the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in	the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑ None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑   None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	☑   None     □   □     □   □	
8	Patents planned, issued or pending	☑   None     □   □     □   □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in	🗶 None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     □   □     □   □     □   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □	
13	Other financial or non-financial interests	□ None	
Plea		next to the following statement to indicate your re answered every question and have not altered th	

Date:	4/22/2022
Your Name:	Andrew Young
Manuscript Title:	Treatment of trigeminal neuralgia in older adults: a narrative review
	based on literature published between 2005 and 2021.
Manuscript Number (if known):	JOMA-2022-OP-01(JOMA-22-2)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			ne all entities with whom you have this tionship or indicate none (add rows as ded)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	ng of the work
1	All support for the present manuscript (e.g.,	X	None	
	funding, provision of			
	study materials,			Click the tab key to add additional rows.
medical writing, article processing charges, etc.) No time limit for this item.				
			Time frame: past 36 mor	iths
2	Grants or contracts from	X	None	
	any entity (if not indicated in			
	item #1 above).			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑ None	
4	Consulting fees	☑   None     □   □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑   None     □   □     □   □	
6	Payment for expert testimony	☑ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	☑   None     □   □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑   None     □   □	
10	Leadership or fiduciary role in	🗷 None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☑   None     □   □     □   □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □	
13	Other financial or non-financial interests	□ None	
Plea		next to the following statement to indicate your re answered every question and have not altered th	

Date:	5/21/2022 Noboru Noma		
Your Name:			
Manuscript Title:	Treatment of trigeminal neuralgia in older adults: a narrative review		
	based on literature published between 2005 and 2021.		
Manuscript Number (if known):	JOMA-2022-OP-01(JOMA-22-2)		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			ne all entities with whom you have this tionship or indicate none (add rows as ded)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planni	ng of the work	
1	All support for the present manuscript (e.g.,	X	None		
	funding,				
	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.			Click the tab key to add additional rows.	
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	X	None		
			1		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)Specifications/Comments (e.g., if payments were made to you or to your institution)		
3	Royalties or licenses	☑ None		
4	Consulting fees	☑   None     □   □     □   □     □   □		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑   None		
6	Payment for expert testimony	X None		
7	Support for attending meetings and/or travel	☑   None     □   □     □   □		
8	Patents planned, issued or pending	☑   None     □   □     □   □		
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None		
10	Leadership or fiduciary role in	🗶 None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	other board, society, committee or advocacy group, paid or unpaid			
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑   None     □   □     □   □		
13	Other financial or non-financial interests	□ None		
Please place an "X" next to the following statement to indicate your agreement:				